Table 1:
Trial Sizes and Power Calculation for Active Controlled Trials with TDF/FTC Control Groups
| Trial | Incidence Rate Ratio | Required | |||
|---|---|---|---|---|---|
| Null Hypothesis | Alternative Hypothesis | Incident HIV+ | Participants | Person Years | |
| DISCOVER*,1 | 1.62 | 1.00 | 106 | 5,400 | 8,756 |
| HTPN 083+,1 | 1.23 | 0.75 | 174 | 4,500 | 10,400 |
| HPTN 084+2 | 1.00 | 0.54 | 111 | 3,200 | 7,200 |
+
randomization: Injectable cabotegravir v. Daily oral tenofovir disproxil fumerate/emtricitabine
*
randomization: Daily oral tenofovir alafenamide/emtricitabine v. Daily oral tenofovir/emtricitabine
1.
Population: men who have sex with men and transgender women
2.
Population: cis women in subsaharan Africa